A phase III study comparing nivolumab with nivolumab plus docetaxel in patients with previously treated advanced non-small-cell lung cancer: a randomized phase II/III trial(TORG1630)
Phase of Trial: Phase II/III
Latest Information Update: 12 Apr 2018
At a glance
- Drugs Nivolumab (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms TORG1630
- 11 Dec 2017 Status changed from not yet recruiting to recruiting.
- 23 Apr 2017 Planned initiation date changed from 1 Jul 2017 to 1 Aug 2017.
- 03 Feb 2017 Trial phase changed from III to II/III. Primary endpoints amended. Trial focus changed. (TU to TU, AR).